Caly für 0,49 und keiner kauft !

n/a    16:19:37    0.55    4'000  
n/a    16:18:57    0.545    2'500  
n/a    16:18:23    0.54    600  
n/a    16:17:33    0.54    700  
n/a    16:17:17    0.54    1'000  
n/a    16:17:17    0.54    3'500  
n/a    16:14:54    0.57    100'000  
n/a    16:13:56    0.54    4'000  
n/a    16:10:04    0.545    2'000  
n/a    16:08:45    0.545    1'050  
n/a    16:06:21    0.545    17'500  
n/a    16:05:43    0.545    50'000  
n/a    16:05:06    0.545    500  
n/a    16:04:41    0.55    722  
n/a    16:02:24    0.545    5'000  
n/a    16:01:49    0.545    2'500  
n/a    16:01:44    0.545    1'500  
n/a    16:01:42    0.55    2'500  
n/a    16:01:42    0.55    10'500  
n/a    16:01:40    0.545    2'500  

da deckt sich wer ein...

vielleicht nochmal zuschlagen. ein wenig kohle hab ich noch. ;O)

PLUS schließen, auch wenn´s bis dahin noch ca. 10% sind.

n/a    16:27:49    0.55    2'500  
n/a    16:27:14    0.55    1'000  
n/a    16:27:14    0.55    10'000  
n/a    16:27:13    0.55    17'500  
n/a    16:26:56    0.545    1'000  
n/a    16:25:19    0.55    25'000  
n/a    16:24:15    0.55    2'500  
n/a    16:23:19    0.55    25'000  
n/a    16:22:53    0.55    2'500  
n/a    16:22:25    0.55    3'000  

Wette auf unverändert +/- 1 cent.  

daytrading, schnelles Geld..

jetzt den richtigen Rhytmus finden !!

Gruß
leo

Bei mir nicht !?

Grüße

Kade_I

ging ja ganz schön zu.
Spanne von 0,50- 0,64 war ja alles vorhanden.

Jap.War ein wenig Bewegung drin. ;O) Bin mal gespannt, ob und wann die nächste News kommt. Vielleicht Donnerstag. Gestern gingen große Pakete über die Theke.  

mein Kursziel ist eher mittelfristig bei 2 $ so Ende Mai 2004

ich sag nur Rapid Urintest mehr brauch ich nicht zu sagen denke ich

den 2$ so kurzfristig. da müssen schon richtige verträge kommen, denke ich. die werden auch kommen, aber ob so schnell? was meinste lucky?

The CRADA between Calypte and the CDC provides for the development of a test to estimate the incident HIV infections (of less than 6 months duration) in a population survey. The purpose of the test is to provide a simplified and rapid format that can be performed in resource poor settings and remote outreach locations as a public health surveillance tool. The test should be particularly suitable for settings with limitations in blood collection capacity, laboratory facilities, or specimen transport. The test will be designed to provide invaluable information to Public Health agencies concerning the course of the HIV pandemic, such as identifying populations where new infections are occurring most frequently, allowing agencies to measure the effectiveness of prevention efforts in specific risk groups, and identifying high-incidence cohorts for prevention trials (e.g. microbicide, vaccine etc).

Calypte recently announced that it had obtained a non-exclusive license from the CDC to manufacture a serum enzyme Immunoassay test that can measure the proportion of infections that are recently acquired (less than 6 months) for use in estimating HIV incidence. This assay is a laboratory based technology that is performed on samples from individuals previously tested and found to be positive for HIV antibodies. Such a test could have applications in helping public health officials to determine which populations have the highest rate of new infections, and by extension, where they need to focus their intervention efforts.

Dr. Richard George, President and CEO of Calypte commented that "A simplified and rapid format for serologic assays to estimate HIV incidence is a logical progression and refinement of the currently used, laboratory based EIA. The ability to perform tests for recent infection for public health surveillance purposes in all types of environments will dramatically expand the use and reduce the cost of incidence testing used to monitor the effectiveness of HIV prevention programs."

Tony Cataldo, Executive Chairman of Calypte, stated, "Calypte is pleased to have completed this second agreement with the CDC and to provide science that will allow Public Health agencies to focus their resources on HIV and AIDS prevention measures that can be shown by empirical data to be effective."

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

Company Contact:
Dr. J. Richard George, President and CEO
(510) 749-5100
rgeorge@calypte.com


Investor Relations Contact:
Tim Clemensen
Rubenstein Public Relations
212-843-9337
tclemensen@rubensteinir.com

SOURCE Calypte Biomedical Corporation

Dr. J. Richard George, President and CEO of Calypte Biomedical
Corporation, +1-510-749-5100, rgeorge@calypte.com; or Investor: Tim Clemensen
of Rubenstein Public Relations, +1-212-843-9337, tclemensen@rubensteinir.com,
for Calypte Biomedical Corporation

www.calypte.com

Copyright (C) 2004 PR Newswire. All rights reserved.

gruß an alle von
Smoky

ALAMEDA, Calif., Apr 14, 2004 /PRNewswire-FirstCall über COMTEX/ -- Calypte Biomedical Corporation (OTC Anschlagbrett: CYPT), eine Firma, die teilnahm, an dem Entwickeln der schnellen Tests für HIV Diagnose und der Entwickler und der Marketingspezialist der einzigen zwei FDA-ANERKANNTEN Tests des Antikörpers HIV-1, die auf Urinproben benutzt werden können, sowie einen zusätzlichen Test des FDA-ANERKANNTEN Antikörper des Serums HIV-1 westlichen Flecks, verkündeten heute, daß er ein CRADA -- eine kooperative Forschung und Entwicklung Vereinbarung -- mit den Mitten zur Krankheit-Steuerung und zur Verhinderung (CDC) für die Entwicklung einer einzigartigen neuen HIV schnellen Blutprobe durchgeführt hat. Wie gegenwärtige schnelle Testproben ist die vorgeschlagene Vorrichtung, damit Diagnosegebrauch HIV Antikörper ermittelt, aber sie ist auch für Gebrauch in den Bevölkerung Studien, den Anteil Infektion HIV-1 zu schätzen, die in den letzten sechs Monaten aufgetreten sind. Diese Probe benutzt ein eigenes recombinant Protein, das die Aminosäurereihenfolgen einschließt, die von den immunodominant Regionen des Transmembraneglucoproteids (gp41) gekennzeichnet werden gekennzeichnet von den mehrfachen Formationsgliedern HIV-1 der Gruppe M. Das CRADA zwischen Calypte und der CDC stellt für die Entwicklung eines Tests zur Verfügung, um die Ereignis HIV Infektion (von weniger als 6 Monaten Dauer) in einer Bevölkerung Übersicht zu schätzen. Der Zweck des Tests ist, vereinfacht zur Verfügung zu stellen und schnelles Format, das in in den schlechten Einstellungen und der Direktübertragung des Hilfsmittels durchgeführt werden kann, übertreffen Positionen als Überwachungwerkzeug des öffentlichen Gesundheitswesens. Der Test sollte für Einstellungen mit Beschränkungen in der Blutansammlung Kapazität, im Labor-Service oder im Probestücktransport besonders verwendbar sein. Der Test ist entworfen, um unschaetzbare Informationen zu den Agenturen des öffentlichen Gesundheitswesens hinsichtlich sind des Kurses des pandemic HIV zur Verfügung zu stellen, wie Kennzeichnen der Bevölkerungen, in denen neue Infektion am häufigsten auftritt, Lassen der Agenturen die Wirksamkeit der Verhinderungbemühungen in den spezifischen Gefahr Gruppen messen und Kennzeichnen der Hochausdehnung Kohorten für Verhinderungversuche (z.B. microbicide, des Impfstoffs usw.). Calypte verkündete vor kurzem, daß es eine nicht-exklusive Lizenz von der CDC erreicht hatte, einen Serumenzym Immunoassay Test herzustellen, der den Anteil Infektion messen kann, die vor kurzem (weniger als 6 Monate) für Gebrauch erworben werden, wenn man HIV Ausdehnung schätzt. Diese Probe ist eine Labor gegründete Technologie, die an den Proben von den Einzelpersonen durchgeführt wird, die vorher geprüft werden und, die gefunden sind, um für HIV Antikörper positiv zu sein. Solch ein Test könnte Anwendungen haben, wenn er Beamten des öffentlichen Gesundheitswesens half, festzustellen, welche Bevölkerungen die höchste Rate der neuen Infektion haben und durch Verlängerung, in der sie ihre Intervention Bemühungen fokussieren müssen. Dr. Richard George, Präsident und CEO von Calypte kommentierte, daß "A vereinfachtes und schnelles Format, ist damit serologic Proben HIV Ausdehnung eine logische Weiterentwicklung und eine Verfeinerung von verwendet z.Z. schätzen, Labor gegründetes EIA. Die Fähigkeit, Tests für neue Infektion zu den Überwachungzwecken des öffentlichen Gesundheitswesens in allen Arten Klimas durchzuführen erweitert drastisch den Gebrauch und verringert die Kosten der Ausdehnung prüfend verwendet, um die Wirksamkeit der HIV Verhinderung programs." zu überwachen; Tony Cataldo, der Executivvorsitzende von Calypte, angegeben, "Calypte freut, sich diese zweite Vereinbarung mit der CDC durchgeführt zu haben und Wissenschaft zur Verfügung zu stellen, die Agenturen des öffentlichen Gesundheitswesens ihre Betriebsmittel auf HIV und AIDS-RICHTEN läßt Verhinderungsmaßnahmen, die durch empirische Daten gezeigt werden können, um effective." zu sein

Keep your eyes on this company! The Sciax Wolf Pack is a highly modularized opto-electronic remote viewing system used by law enforcement and military personnel. The reconfigurable, multi-operational design of Wolf Pack makes the system ideal for many applications in physical security, drug and contraband interdiction, tactical response, protective security, and evidence recovery. Wolf Pack electronics and optical components are built to high standards of durability, allowing successful deployment in harsh conditions that would prohibit the use of many conventional imaging systems.

The stock closed yesterday at sixteen cents a share.

In case you are not familiar with the company: Sciax is an emerging leader in defense imaging systems for law enforcement and military personnel engaged in counter-terrorism and other special security operations. Sciax America Inc. and Sciax Technology Inc. are wholly owned subsidiaries of UGOMEDIA INTERACTIVE. A name change from UGOMEDIA INTERACTIVE to SCIAX CORPORATION is pending.

Sciax is the manufacturer of Wolf Pack, the company's tactical remote viewing system used by law enforcement and military organizations in North America and Europe. Customers include military and law enforcement agencies of the US and German Governments, contraband interdiction units of Canada Customs and LAPD-SWAT.

Stocks showing interesting activity yesterday were: Nano-Proprietary Inc. (OTCBB:NNPP) up .39% on 119,300 shares traded, Calypte Biomedical Corporation (OTCBB:CYPT) down 4.1% on 1.2 million shares traded and Media Services Group Inc. (Nasdaq:MSGI) down 18.5% on 1.5 million shares traded.

Commentary:

"U.S. gasoline could average over $1.80 nationwide this summer, and has already gone higher in some areas of the country. Poor planning, stringent emissions rules, and record demand by India and China are the culprits, according to many gasoline analysts; oh, and don't forget those gas-guzzling SUV's so beloved by Americans," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: www.WallStreetNewsAlert.com.

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 17 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at www.wallstreetnewsalert.com and select the "join now" button.

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated twenty-four thousand dollars for coverage of UgoMedia Interactive Corp. (Pink Sheets:UGMI), by a third party (Alex Consulting Inc.), who is non-affiliated and may hold a significant position in the stock, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive shares for extension of its services. Any shares will be disclosed at such time that WSCF is aware of a clients desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock. Market commentary provided by Sonja Rudd.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

SOURCE: Wall Street Capital Funding LLC

INVESTMENT OPINION

By Staff
CONTACT: Wall Street News Alert Email: info@wallstreetnewsalert.com URL: www.wallstreetnewsalert.com



(C) 2004 PRIMEZONE, All rights reserved.

-0-



INDUSTRY KEYWORD: Advertising
SUBJECT CODE: INVESTMENT OPINION
Analyst Recommendations